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Summary
Objectives: The present study characterized and determined the prevalence of
mycobacterial diseases (tuberculosis (TB) and non-tuberculous mycobacteria
(NTM)) as a cause of hospitalization among HIV-infected subjects consecutively
admitted to a large metropolitan hospital during 2001/2002.
Methods: Hospital discharge diagnoses were established for 521 HIV-positive
patients.
Results: Respiratory disease accounted for 49% of the admissions. Community
acquired pneumonia (CAP) was the main cause of respiratory disease (52%) followed
by Pneumocystis carinii (PCP, 24%), non-tuberculous mycobacteria (NTM, 11%) and
Mycobacterium tuberculosis (TB, 9%). Mycobacterium tuberculosis disease was
established using bacteriological, clinical and radiographic criteria. NTM disease
was defined following the American Thoracic Society criteria. NTM was disseminated
in the majority of cases (19 Mycobacterium avium complex (MAC), one Mycobacter-
ium kansasii). Nine patients had respiratory disease (seven MAC, one Mycobacterium
fortuitum, one Mycobacterium kansasii) and one had gastrointestinal disease caused
by MAC. Mortality was 10% for NTM disseminated cases; none of the TB patients died
over the course of the study. The length of hospitalization for NTM patients was longer
(15  13 days) than for other respiratory cases (10  10, p = 0.04).* Corresponding author. Tel.: +1 305 243 4072; fax: +1 305 243 4687.
E-mail address: mmiguez@med.miami.edu (M.J. Miguez-Burbano).
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Non-tuberculous mycobacteria (NTM) are ubiquitous
organisms, different from Mycobacterium tubercu-
losis (TB), and represented by more than 65 differ-
ent species.1 The most frequent forms of NTM
include Mycobacterium avium complex (MAC,
61%),Mycobacterium fortuitum (19%) andMycobac-
terium kansasii (10%), with smaller percentages of
Mycobacterium gordonae and Mycobacterium che-
lonae.1,2 The routine application of the liquid med-
ium-based Bactec 460 TB system (Becton Dickinson
Diagnostic Instrument Systems, Sparks, MD) and the
DNA hybridization-based assay has increased the
sensitivity and specificity of NTM diagnosis and sig-
nificantly reduced the time required for isolation
and identification.
In a substantial percentage of cases, patients
with NTM have underlying conditions (genetic or
structural in nature) or severe immunosuppression
(congenital or acquired)3—6 that increase their vul-
nerability to NTM. Some, but not all, NTM patients
have a history of underlying chronic lung disease.7
In recent years, NTM disease has become parti-
cularly relevant because of the HIV pandemic.8—10
The atypical mycobacterium Mycobacterium
avium complex (MAC) has emerged as one of
the frequent opportunistic infections isolated in
AIDS patients. The frequency of diseases due to
NTM has been rising worldwide as well as in the
USA, and NTM may be a frequent and considerable
cause of morbidity/mortality in immunocompro-
mised subjects.11 Prior to the introduction of
highly active antiretroviral therapy (HAART), it
was estimated that up to 43% of AIDS patients
would acquire NTM during their lifetime.8,12
Delayed diagnosis may, thus, result in increased
mortality rates.10
As the prevalence of HIV in Florida, particularly in
Miami, is one of the highest nationwide, it is
expected that TB and NTM disease will become
relatively more significant.13 Because this is not
yet a reportable illness in the USA, the task of
estimating incidence and prevalence has been dif-
ficult.9,14 The clinical significance of NTM infections
in HIV seropositive patients has not been clearly
defined, and the importance of NTM diseases as a
cause of hospitalization remains uncertain. The
present study was designed to characterize, deter-
mine the prevalence and better appreciate the roleof mycobacterial diseases, particularly NTM, as a
cause of hospitalization among HIV-infected sub-
jects admitted to a large metropolitan hospital,
during the HAART era (2001/2002). The present
study will provide the data necessary to revise
strategies in clinical, microbiological, and public
health approaches to mycobacterial disease and will
provide updated information on the HAART era.Materials and methods
Study subjects
Men and women 18 years of age or older with
confirmed HIV infection, and consecutively
admitted to Jackson Memorial, a central referral
hospital, were eligible for enrollment. Jackson
Memorial Hospital, a 479-bed tertiary care teaching
institution, is affiliated to the University of Miami.
The hospital has the largest tuberculosis clinic in
Dade County and is the major AIDS treatment center
in the region. All mycobacterial isolates from this
area are referred to the Mycobacteriology Labora-
tory at Jacksonville for final identification.
Following admission, stable patients were con-
tacted and fully informed about the study. Written
informed consent was obtained from all partici-
pants. The Human Studies Committee of the Uni-
versity of Miami School of Medicine Institutional
Review Board approved the project.
A physician with experience in the care of HIV-
infected individuals completed all the enrollment
procedures. Following an interview, a physical
examination was conducted. Blood was drawn to
determine CD4 cell count as part of the admission
laboratory diagnostic procedures. Immunological
tests were ordered, if necessary, as part of the study
procedures.
Medical information
Research data were derived from two main sources:
medical records and study questionnaires. A physi-
cian recorded complete past and family medical
history of opportunistic infections, allergies and
chronic illnesses. History of medication included
past and current antiretrovirals, anti-TB prescrip-
tions and chemoprophylaxis. Our definition of
HAART was a combination of three drugs thatConclusions: NTM disease along with its related mortality is a significant pathology as
a cause of hospitalization among HIV-infected individuals.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
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nucleoside reverse transcriptase inhibitor (NNRTI),
or any regimen containing more than one PI or more
than 4 antiretrovirals. Participants were classified
as taking HAART if: 1) they reported to both the
study interviewer and medical team at admission
that they were taking HAART; 2) viral load was not
greater than 50 000 copies/ml and a reduction from
a previous viral load test was evident; and 3) phar-
macy records indicated that participants obtained
their prescribed medication.
We defined ‘effective HAART’ as those antiretro-
viral combination regimens that permitted unde-
tectable viral loads to be achieved; otherwise,
therapeutic regimens were classified as ‘non-effec-
tive HAART’.
The medical study team, comprised of three HIV
clinician/researchers, compared and validated the
data. All available clinical data, antiretroviral med-
ications, antimicrobial treatments, laboratory
results, radiology studies (i.e., X-rays, scans) and
responses to treatments were reviewed to confirm
the diagnosis. Medical chart review permitted the
most precise cause of disease (i.e., infectious
pathogen) to be defined.
Hospitalization
Computerized diagnostic code data included num-
ber of previous admissions to the hospital, date
of present admission, length of stay, and presump-
tive admission diagnosis. Discharge data coding
included the main discharge diagnosis and a list
of diagnostic exams and procedures that had been
performed.
Diagnostic criteria for TB disease
Two out of three criteria were used to confirm TB
disease: (1) acid-fast bacilli (AFB) culture, positive
for TB from any tissue or fluid; (2) positive smear;
and (3) clinical (signs/symptoms), abnormal chest X-
ray and CT scan compatible with TB disease.15
Diagnostic criteria for NTM disease
Confirmation of NTM disease was based on American
Thoracic Society (ATS) criteria16: (1) repeated iso-
lation of atypical mycobacteria from three or more
respiratory samples (i.e., culture + AFB); and (2) an
abnormal chest radiograph, or the presence of one
or more symptoms indicative of pulmonary disease
which responded to therapy. NTM pulmonary disease
was established with isolation/culture in respiratory
samples (i.e., sputum, bronchial wash) and negative
blood culture. Extrapulmonary disease was diag-nosed when mycobacteria were isolated from only
one location other than lung, pleura, blood, or
bone marrow. Disseminated NTM disease was
established when multiple organs were involved,
when mycobacteria were isolated from blood or
bone marrow, or when infection manifested as
miliary disease.
Chest radiograph reports were abstracted. The
pattern and location of parenchymal infiltrates
(interstitial, alveolar, reticulonodular, or mixed)
and/or cavities were noted. The size and location
of pleural effusions or fibrosis were also summar-
ized.
Mycobacteria strains
Clinical specimens were sent for routine mycobac-
terial cultivation to the Mycobacteriology Labora-
tory of the Florida State Department of Health.
Samples were processed using Bactec 12B and
Bactec 13A liquid medium or solid media, such
as Lowenstein—Jensen slants or Middlebrook
7H10 or 7H11 slants or plates. Bactec cultures were
considered to be positive if actively growing (test
culture with growth index >300). Isolates were
characterized using standard microbiological
criteria.
PCR restriction digestion with
endonucleases BstE II and Hae III
Mycobacteria from liquid or solid media were sus-
pended in 250 ml of 10 mM Tris-EDTA and centri-
fuged. The clinical specimens were centrifuged at
14 000 rpm for 5 min. The pellets were washed
twice and DNA was isolated using standard proce-
dures. Amplifications were carried out in thin-wall
reaction tubes using an automated thermal cycler
and according to the manufacturer’s instructions
(Perkin—Elmer, GeneAmp PCR System 9600). Posi-
tive and negative controls were included in all the
experiments with clinical specimens.
Amplicons were digested with endonucleases
BstE II and Hae III. Aliquots of amplified samples
(15 ml) were loaded on 3% NuSieve agarose gels in
Tris-acetate-EDTA (TAE) buffer and subjected to
electrophoresis in mini gel boxes for 60 min at
160 V. The gels were stained with ethidium bromide
at 0.5 mg/ml, observed under ultraviolet light for
specific DNA bands and photographed.
HIV disease status
The diagnosis of AIDS was made using the Centers for
Disease Control surveillance criteria.17 CD4 cell
counts and viral load measurements were
50 M.J. Miguez-Burbano et al.abstracted from medical records or obtained at
admission for the study.
Flow cytometry was used to quantify the percen-
tage and absolute numbers of T lymphocyte sub-
populations. A four-color direct immunofluorescence
procedure (Becton Dickinson, San Jose, CA) was used
to determine the percentages and absolute counts of
the helper inducer T cells (CD3+/CD4+).
A reverse transcriptase polymerase chain reac-
tion (Roche) was used to quantify HIV viral load. The
current version of this assay has a reportable range
of >200 to 750 000 RNA copies per ml of plasma.
Statistical analysis
The data were analyzed using SPSS version 11 and
SAS 8. Following descriptive statistical analyses,
mean variables were compared using Student’s t-
test and one-way ANOVA procedures. The relation-
ships between main variables were examined with
Pearson’s correlation coefficient. In the final model,
regression logistic analyses were used to predict the
risk factors associated with the development of
mycobacterial disease.Results
Study population
Five hundred and twenty-one HIV-positive patients
(300 men, 221 women) were admitted to JacksonTable 1 Principal characteristics of study group.
Variable Study subjects (n = 521
Gender
Male 300 (58%)
Female 221 (42%)
Age (years) 42  9
Ethnicity
African—American 315 (61%)
Haitian 90 (17%)
Hispanic 92 (18%)
Caucasian 20 (4%)
CD4 cell count (cells/mm3) 131  177
Viral load (copies/ml) 262126  512291
AIDS 416 (80%)
HIV 105 (20%)
HAARTb
Yes 203 (39%)
No 318 (61%)
a NTM, Non-tuberculous mycobacteria.
b HAART, highly active antiretroviral therapy.Memorial Hospital between September 2001 and
December 2002 and enrolled in the study. The main
characteristics of the study subjects are presented
in Table 1. Participants ranged in age from 20 to 72
years (42  9 years). More than half (63%) of the HIV-
infected patients admitted to regularly using at
least one illicit drug at some point during his or
her life. One hundred and fifty-five participants
(30%) admitted to using some form of illegal sub-
stance within 30 days of their interviews. The most
common drugs used were crack/cocaine (44%) and
marijuana (44%). Other illicit drugs (amphetamines,
heroin) were regularly used by less than 3% of the
HIV study participants. A tendency for crack/
cocaine users to be hospitalized with NTM (OR = 2,
95% CI 1—4.2, p = 0.08) was observed. No other
relationship was observed between drug abuse
and mycobacterial disease.
Despite the prevalent use of drugs, only 7%
reported drug abuse as the source of HIV infection
whereas most study participants reported unpro-
tected sex as a route of transmission. Most partici-
pants (89%) reported unprotected heterosexual
contact, 3% reported homosexual transmission,
and only 1% reported bisexual contact. Men who
had sex with men were four times more likely to
have NTM as a cause of hospital admission (OR = 4.8,
95% CI 1—20, p = 0.05). On the contrary, all TB cases
occurred among heterosexuals.
More than half of the participants were African—
American (61%), 18% were Hispanic, 17% Haitian,
and the remaining 4% were Non-Hispanic white. As) NTMa (n = 30) Tuberculosis (n = 24)
21 (70%) 15 (63%)
9 (30%) 9 (37%)
39  9 43  8
20 (67%) 6 (25%)
4 (13%) 11 (46%)
6 (20%) 6 (25%)
0 1 (4%)
79.2  167.53 132.3  132.45
386811  277978 293225  202538
30 (100%) 24 (100%)
0 0
12 (40%) 9 (38%)
18 (60%) 15 (62%)
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ing gender, age or income were observed between
HIV-infected subjects diagnosed with NTM disease
(n = 30) and those diagnosed with TB (n = 24). Most
of the NTM patients were African—American (67%)
and no case was observed among Non-Hispanic
Whites. On the contrary, a significantly lower pro-
portion of African—Americans were hospitalized
with tuberculosis. TB patients were predominantly
Hispanic Blacks (Haitian, 46%). A significantly higher
proportion of Hispanic Blacks (12%) were diagnosed
with tuberculosis than African—Americans (2%;
X2 = 16, p < 0.0001). The proportion of White His-
panics (6.5%) with TB was higher than the percen-
tage of African—Americans that developed TB (2%;
X2 = 3.8, p = 0.05). Almost half of the NTM patients
(40%) and 38% of the TB patients reported being on
HAART at admission.
Discharge diagnosis
Respiratory diseases accounted for 49% of the total
admissions. Community acquired pneumonia (CAP)
was the main cause of respiratory disease (52%),
followed by Pneumocystis carinii (PCP, 24%), NTM
(11%) and TB (9%).
Mycobacterial isolation in HIV-infected
subjects
Non-tuberculous mycobacteria were isolated in the
sputum, smear and/or cultures of 63 HIV-infected
patients (12% of the total study population). In
almost half of these cases (48%), the isolated NTM
was the cause of the disease (as per ATS criteria). In
two patients, both NTM and TB were isolated (TB
with MAC and M. gordonae, respectively), but the
final diagnosis was TB. Three other presumptive
NTM cases were excluded from the analyses because
NTM was not isolated. Excluding the above five
cases, the prevalence of NTM disease was 11% in
patients with a lower respiratory infection (n = 265).
The majority of the patients with NTM disease (67%)
had disseminated disease (19 MAC and 1 M. kansa-
sii). The remaining 10 cases involved respiratory
disease (seven MAC, one M. fortuitum, one M.
kansasii) or a gastrointestinal illness (MAC). TB
was diagnosed in 24 HIV-infected patients. The
prevalence of tuberculosis in the current study
was 9%.
The most frequently isolated NTM was MAC (71%,
n = 45) with 32% in blood and 68% in sputum, fol-
lowed by M. fortuitum in sputum (n = 12) and M.
kansasii (n = 6) with 83% from sputum and one speci-
men in blood. Single isolations in sputum occurred
for M. chelonae, M. gordonae, and M. simiae.HIV disease status
On average, the study population had been HIV
positive for 7  6 years. According to CDC criteria,
80% of the patients had AIDS status and the remain-
ing 20% were HIV symptomatic. The mean CD4 cell
count of the total group was 131  177/mm3 with
one third (33%) of the group having cell counts more
than 200/mm3. The mean viral load was
262 126  512 291 copies/ml; 5.6% (n = 17) had
undetectable viral load levels. Only 39% of the study
population was using HAARTand the rest were either
receiving one medication or none (61%).
NTM/TB cases and HIV
A greater proportion of NTM patients (93%) had CD4
cell counts <200/mm3 as compared to TB patients
(79%, p = 0.003). It needs to be noted that although
most patients with NTM (73%) had less than 50 CD4
cells, 17% had between 51 and 200 cells and 10% had
cell counts of more than 200. Univariate analyses
demonstrated a significantly higher risk of being
hospitalized with NTM disease among patients with
CD4 cell counts below 200 (OR = 6.6, 95% CI 1.5—
24.6, p = 0.003) when compared to patients hospi-
talized with TB disease. Additional analyses (CAT-
MOD) indicated that after controlling for HAART,
those with CD4 cell counts below 200/mm3 were
three times more likely to be hospitalized for NTM
than for any other non-respiratory cause (p = 0.04).
CD4 cell counts were significantly lower in partici-
pants who developed disseminated NTM disease
(30.9  47) as compared to those with a localized
disease (80.5  76.4, p = 0.05). No significant dif-
ferences in mean viral load were observed among
patients hospitalized with localized, disseminated
NTM disease or admitted with TB. Additional ana-
lyses demonstrated that viral loads of TB patients
tended to be significantly higher than the viral
loads of patients hospitalized with non-infectious
diseases (391 035  77 875 versus 196 017  21 850,
p = 0.07). Of interest, however, is the fact that
patients with NTM had significantly higher viral loads
than those with non-infectious diseases (195 145 
21 725; p = 0.03).
At admission, less than half of the study group
was using HAART (39%). Forty percent of the NTM
group and 38% of the TB patients were administered
HAART. CD4 cell counts were significantly lower in
the non-HAART group (HAART: 169.8  211 versus
non-HAART: 106.48  149, p = 0.0001). Of those
subjects receiving HAART, 6% developed NTM.
Nevertheless, none fulfilled our criteria of ‘effec-
tive HAART’ (undetectable viral loads) even though
52 M.J. Miguez-Burbano et al.viral burden was reduced under the current regi-
mens.
At admission, 25% of the NTM cases reported
taking azithromicin, 40% of the cases were pre-
scribed but were not adherent, and the remaining
population was not taking any prophylaxis at the
time of admission.
Clinical and radiographic features
Clinical findings and symptoms of all patients were
non-specific and included cough, fever, chills, fati-
gue, and weight loss. Most patients with TB and NTM
disease had abnormal chest X-rays (TB = 75%,
NTM = 73%). There were some differences in the
radiographic features of NTM disease compared to
TB. One third (33%) of our participants had a bilat-
eral diffuse infiltrate. In contrast to previous studies
describing lingular involvement, the disease was
seen predominantly in the apical lobes (24%), 14%
in the lower lobes with an additional 16% having
involvement of the pleura and effusions. Only 8%
had involvement of the middle lobe or the lingula,
and the remaining percentage (5%) had lymphade-
nopathy.
In chest X-rays the most frequent pathological
lesions of NTM cases included interstitial infiltrates
in 33% of the cases7 contrasting with none among TB
cases. Pleural effusions (20%, n = 6) and lymphade-
nopathies18 were other common abnormalities. In
contrast to previous reports, bronchiectasis was not
the main radiological feature. Chest radiographs
were frequently normal despite active pulmonary
infection during the first 1—2 weeks of the disease,
and subsequent studies demonstrated one of the
above abnormalities.
Mycobacteria and other risk factors
Pre-existing disease
Medical history of a chronic disease (i.e., chronic
obstructive pulmonary disease (COPD), renal dis-
ease) was noted in 21% (n = 110) of the study popu-
lation; only 13% (n = 4) of the patients diagnosed
with NTM had been diagnosedwith a chronic respira-
tory disease. Pre-existing malignant disease was not
associated with either NTM ( p = 0.69) or with TB
( p = 0.83). Past respiratory disease (COPD, TB or
other lower respiratory infections), another poten-
tial risk factor, was not related to increased suscept-
ibility for NTM ( p = 0.24) or TB (p = 0.17). Most of
the study participants who developed a mycobac-
terial disease were malnourished (85% albumin
<3.5 g/dl); mean albumin levels were similar in
patients with NTM (2.8  0.5) and TB (2.6  0.7).
Significant differences, however, were evidentwhen patients with disseminated NTM (2.8  0.6)
were compared to those with localized NTM disease
(2.1  0.27, p = 0.03).
Tobacco use
The overall rate of current smoking was 59.8% for
men and 40.2% for women. A large percentage of the
non-smoking men (54%), and 46% of the non-smoking
women reported never using tobacco. Though smok-
ing patterns were similar in NTM and TB patients,
participants who developed a localized respiratory
disease were more likely to be heavy smokers
(17  14 mean cigarettes/day) relative to those
who developed a disseminated disease (7  4).
Morbidity/mortality
Hospital duration and classification score for AIDS
hospitalization19 were evaluated. The length of
hospital stay varied from 1 to 78 days with a mean
across the study group of 9.7  10 days. TB patients
were hospitalized for an average of 7.7  2.6 days,
which was significantly shorter than the duration of
patients with non-respiratory infections (9  10
days, p = 0.02). Furthermore, diagnosis and time
to initiate treatment was significantly lower in TB
patients (4.4  1.1 days as compared to 27  6 days,
p = 0.001) in the NTM patients.
Of interest, there was a significant positive
correlation between number of days to initiate
therapy and CD4 cell counts (p = 0.04). Univariate
analyses indicated that if CD4 cell counts were
below 100/mm3, physicians were more likely to
diagnose NTM in the first week of admission (95% CI
1.03—6.64, p = 0.04). Moreover, if CD4 counts were
dichotomized above and below 200 the mean time
to initiate treatment was 22  5 days as compared
to 50  17 (p = 0.05). Furthermore, three patients
with more than 150 CD4 cells/mm3 required a re-
admission to the hospital before NTM disease diag-
nosis was achieved and twomorewere diagnosed and
treated in the outpatient clinic. In consequence, the
length of hospital stay was longest in the NTM
patients (19.5  4 days, p = 0.02). Univariate ana-
lyses further confirmed that patients with NTM
disease were four times more likely than any
other group to stay longer than the average length
(10 days) for the total cohort (n = 521, p = 0.001).
Table 2 describes the morbidity/mortality char-
acteristics of the patients with mycobacterial dis-
ease. Evaluation of mortality indicated that 10% of
the patients with disseminated NTM disease died
during the hospitalization period (#4 in the classifi-
cation of AIDS hospitalization).19 None of the
patients with TB died during hospitalization.
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Table 2 Morbidity/mortality characteristics of patients with mycobacterial disease.
Variable NTM disease (n = 30) TB disease (n = 24)
Patients with localized pulmonary mycobacteria 9a 19
Disseminated disease 20 (67%) 5 (21%)
Prevalence 11% 9%
Mortality 3 (10%) None
a An additional participant had a GI NTM disease.Multivariate analyses
Multivariate analyses in this group of hospitalized
patients indicated that high viral loads (OR = 7,
p = 0.02) and CD4 cell counts less than 200/mm3
(OR = 2, p = 0.05) predict NTM disease. When data
were analyzed among those respiratory-compro-
mised, cigarette smoking also remains significant
(OR = 1.8, p = 0.05).
Our findings regarding disseminated NTM disease,
however, differ and reveal that CD4 cell counts
below 50, instead of 200, are the main variable
associated with dissemination (OR = 13, p = 0.001)
as well as detectable viral loads (OR = 4, p = 0.42).
HAART, race/ethnicity, self-reported route of
HIV transmission were no longer significant in the
models.Discussion
To our knowledge, this is the first prospective study
to evaluate both tuberculous and non-tuberculous
mycobacteria as causes of hospitalization in HIV-
infected subjects during the HAART era. Results of
this investigation indicate that, after community
acquired pneumonia (CAP) and Pneumocystis carinii
pneumonia (PCP), NTM is the third most frequent
cause of hospitalization due to a lower respiratory
disease. Furthermore, the prevalence of NTMdisease
in hospitalized subjects is actually higher (11%) than
the prevalence of TB disease (9%) in an area that has
one of the highest TB rates among cities in theUSA. In
agreement with these findings, Benator and Gordin20
have reported that mycobacterial disease is now the
secondmost frequent cause of illness in AIDS patients
receiving PCP prophylaxis. In the present study, half
of those with isolated NTM met the ATS criteria for
NTM disease. Diagnosis was confirmed in 30 patients
resulting in a 6% prevalence of NTM disease consis-
tent with previous studies reporting prevalence rates
of between 3 and 13%.4,8,10,12,21—23
The confirmed isolation of NTM in 11% of the HIV-
infected subjects is in agreement with previous
international reports.8,10,12,21—23 Data suggest that
the frequency of NTM infection and disease isincreasing worldwide and geographically varies
from 5 to 37% in Latin America to 25 to 50% in
European studies.8,18,23 Although strongly associated
with the HIV epidemic, global increases in NTM cases
have been observed in both HIV-infected and non-
infected populations.8,10,12,21,24 Nonetheless,
O’Brien et al. in a report from Australia found that
the incidence had increased most notably in non-
HIV-infected individuals (4.4/100 000 population
versus 1.7/100 000 in HIV-infected individuals).25
In agreement with earlier studies1,7,12,14,21,
22,24,26—29 the organisms most commonly isolated
as the cause of NTM disease in the present report,
were M. avium and M. intracellulare (collectively
known as the Mycobacterium avium complex
(MAC)), followed by M. fortuitum and M. kansasii.
Most of the NTM cases occurred among African—
Americans, in agreement with Bloch et al.27 and
Pitchenik et al.29 However, data regarding race are
conflicting, with most studies reporting higher rates
of NTM among whites.1,7,12,22,26—29
Although no significant differences between
route of transmission and specific mycobacteria
were observed, a higher prevalence of NTM was
observed among homosexuals. This is in accord with
previous publications noting higher prevalences of
Mycobacterium avium-intracellulare among homo-
sexuals.30—32 In addition, exposure to M. avium
glycopeptidolipid antigens also seems to be more
prevalent in HIV-seropositive homosexuals than
among control populations. Demographic features
and route of transmission, as a potential risk factor,
will require further consideration.
Our findings reveal a higher mortality in NTM
patients (10%) than in TB-infected patients, none
of whom died over the course of the study. Addi-
tionally, NTM patients, particularly those with CD4
counts of less than 200, were diagnosed and treated
later in the course of hospitalization and suspected
only when other diagnoses had been eliminated and
the patient continued to be symptomatic. These
data underscore the importance of continuing to
include NTM in the differential diagnosis of HIV-
infected subjects, even if they have CD4 cell counts
of more than 100.
Physicians treating HIV-infected subjects need to
consider NTM as a potential and frequent cause of
54 M.J. Miguez-Burbano et al.disease. In support of this proposition, O’Brien
et al.13 have suggested that with a decrease in
the incidence of TB, NTM disease will rise. The
prevalence of NTM disease along with its related
mortality show the necessity for considering NTM as
an opportunistic infection and evaluating it as a
reportable disease. This applies to patients with
disseminated disease, particularly those with a
less-indolent course, for whom more days of hospi-
talization are required before final diagnosis. Care-
ful screening will be necessary to ensure specific
treatment, prevent inappropriate chemoprophy-
laxis, and re-hospitalizations to reduce the risk of
resistance or dissemination of NTM disease.
Of importance and in contrast to previous
reports, most of the present NTM cases (67%) were
disseminated; in O’Brien’s study,13 for example, as
many as 80% were pulmonary cases. Although our
study participants had respiratory symptoms, NTM
was mainly isolated in blood (67%), with or without
isolation from respiratory specimens, and only 33%
were from respiratory samples (bronchial wash,
sputum, smear). As expected, lower CD4 cell counts
were observed in those with disseminated disease.
In agreement with previous studies, higher smok-
ing rates were observed in those with NTM disease.25
Our studies extended these published reports by
specifying that the association is relevant only to
pulmonary disease. It should be noted that Myco-
bacterium avium-intracellulare could be recovered
from tobacco, cigarette paper, and cigarette filters
from several cigarette brands, thus providing a
potential explanation for the increased risk of pul-
monary disease.4,14
Malnutrition (lower mean albumin levels) and
lower viral loads associated with NTM pulmonary
disease were, however, unanticipated and require
further evaluation.
The introduction of HAART has dramatically chan-
ged the clinical prognosis for HIV-infected patients in
decreasing mortality, morbidity, and the need for
hospitalization.26 Nevertheless, almost half (40%)
of the patients admitted with NTM disease were
receiving HAART at the time of hospital admission,
although undetectable viral loads had not been
achieved. These data, in agreement with those pub-
lished by Nun˜ez and colleagues,33 emphasize that
even with administration of HAART, subjects with
low CD4 cell counts and detectable viral loads may
still be at increased risk of developing opportunistic
infections (i.e., PCP, NTM). It should be noted that, in
contrast to Nun˜ez’s report, we did not observe a
temporal relationship between the development of
NTM and the receipt of antiretroviral therapy.
The high prevalence of both infection and disease
suggests that the frequency of NTM as a cause ofdisease is increasing, and careful surveillance must
be implemented. Enhanced awareness and addi-
tional culturing for both pulmonary and dissemi-
nated disease may also be related to the
increased reports of NTM disease.16,20 The lack of
systematic reporting of NTM disease in the USA, as
well as in other countries, limits the ability to derive
accurate estimates of infection and disease.27 Bet-
ter methods for early detection and therapy of NTM
disease need to be developed and prevention stra-
tegies implemented. Without appropriate screening
tools, reporting systems, and early diagnosis, the
problem may continue to grow and become a far
more important issue than current rates suggest.Acknowledgments
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